Adherence to treatment and prevalence of side effects when medical abortion is delivered via telemedicine: a prospective observational cohort study during COVID-19

被引:0
作者
Reynolds-Wright, John Joseph [1 ,2 ]
Johnstone, Anne [1 ,2 ]
McCabe, Karen [1 ,2 ]
Evans, Emily [3 ]
Cameron, Sharon [1 ,2 ]
机构
[1] Univ Edinburgh, MRC Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland
[2] NHS Lothian, Chalmers Ctr, Edinburgh, Midlothian, Scotland
[3] Univ Edinburgh, Edinburgh Clin Res Facil, Edinburgh, Midlothian, Scotland
来源
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY | 2022年 / 15卷
关键词
abortion; therapeutic; COVID-19; health services research; mifepristone; patient safety; reproductive health;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The Scottish government introduced legislation during the COVID-19 outbreak to permit medical abortion at home with telemedicine. All women received an initial telephone consultation. For those choosing medical abortion, we provided self-administered medications to eligible women with pregnancies under 12 weeks' gestation. Aims To assess adherence to the recommended abortion drug regimen, with particular focus on the number of misoprostol doses used and the interval between mifepristone and misoprostol administration and the induction-expulsion interval. Additionally, to evaluate use of analgesia, antiemetics and antibiotics, and the side effects, pain and bleeding profile of medical abortion at home. Methods We conducted a prospective cohort study of 663women choosing medical abortion at home via telemedicine at an NHS abortion service in Edinburgh, Scotland between 1 April and 9 July 2020. Interviewer-administered questionnaires were completed at telephone follow-up 4 and 14 days following treatment. Outcome measures were self-reported and included use of mifepristone and misoprostol, induction-expulsion interval (time from misoprostol administration until expulsion of pregnancy), antiemetics, antibiotics, analgesia use, pain scores, rates of side effects, bleeding and preparedness for treatment. Results Among the respondents, 652/663women (98%) answered at least one questionnaire, and 594/663 (89.6%) used both abortion medications as directed (24-72hours between medications). The mean (SD) induction-expulsion interval was 4.3 (4.3) hours. Antiemetics were used by 611/663 (92%), 383/599 (64%) completed the course of prophylactic antibiotics, and 616/663 (93%) used analgesia, with mean (SD) worst-pain scores of 6.7 (2.2) out of 10. Regarding side effects, 510/663 (77%) experienced either nausea, vomiting, diarrhoea or headache, 101/663 (15%) experienced headache and 510/663 (77%) experienced bleeding that was heavier than a period; 554/663, (84%) felt prepared for their treatment by teleconsultation. Conclusion Patients are able to correctly self-administer abortion medications following a telemedicine consultation. Further research is required to optimise pain management and gastrointestinal side effects during medical abortion.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 24 条
  • [1] Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study
    Aiken, A. R. A.
    Lohr, P. A.
    Lord, J.
    Ghosh, N.
    Starling, J.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (09) : 1464 - 1474
  • [2] Pre-emptive effect of ibuprofen versus placebo on pain relief and success rates of medical abortion: a double-blind, randomized, controlled study
    Avraham, Sarit
    Gat, Itai
    Duvdevani, Nir-Ram
    Haas, Jigal
    Frenkel, Yair
    Seidman, Daniel S.
    [J]. FERTILITY AND STERILITY, 2012, 97 (03) : 612 - 615
  • [3] Baird D T, 1988, J Reprod Fertil Suppl, V36, P173
  • [4] Women's experiences of a telemedicine abortion service (up to 12 weeks) implemented during the coronavirus (COVID-19) pandemic: a qualitative evaluation
    Boydell, N.
    Reynolds-Wright, J. J.
    Cameron, S. T.
    Harden, J.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2021, 128 (11) : 1752 - 1761
  • [5] Chief Medical Officer for Scotland, 2020, AB COVID 19 APPR MIF
  • [6] Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic
    Chong, Erica
    Shochet, Tara
    Raymond, Elizabeth
    Platais, Ingrida
    Anger, Holly A.
    Raidoo, Shandhini
    Soon, Reni
    Grant, Melissa S.
    Haskell, Susan
    Tocce, Kristina
    Baldwin, Maureen K.
    Boraas, Christy M.
    Bednarek, Paula H.
    Banks, Joey
    Coplon, Leah
    Thompson, Francine
    Priegue, Esther
    Winikoff, Beverly
    [J]. CONTRACEPTION, 2021, 104 (01) : 43 - 48
  • [7] Opioid Analgesia for Medical Abortion A Randomized Controlled Trial
    Colwill, Alyssa Covelli
    Bayer, Lisa L.
    Bednarek, Paula
    Garg, Bharti
    Jensen, Jeffery T.
    Edelman, Alison B.
    [J]. OBSTETRICS AND GYNECOLOGY, 2019, 134 (06) : 1163 - 1170
  • [8] Dragoman MV, 2021, CONTRACEPTION, V103, P163, DOI [10.1016/j.contraception.2020.17.004, 10.1016/j.contraception.2020.12.004]
  • [9] Pain during medical abortion, the impact of the regimen: A neglected issue? A review
    Fiala, Christian
    Cameron, Sharon
    Bombas, Teresa
    Parachini, Mirella
    Saya, Laurence
    Gemzell-Danielsson, Kristina
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2014, 19 (06) : 404 - 419
  • [10] Prophylactic Pregabalin to Decrease Pain During Medication Abortion A Randomized Controlled Trial
    Friedlander, EmmaKate B.
    Soon, Reni
    Salcedo, Jennifer
    Davis, James
    Tschann, Mary
    Kaneshiro, Bliss
    [J]. OBSTETRICS AND GYNECOLOGY, 2018, 132 (03) : 612 - 618